JP2016526531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526531A5 JP2016526531A5 JP2016518498A JP2016518498A JP2016526531A5 JP 2016526531 A5 JP2016526531 A5 JP 2016526531A5 JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016518498 A JP2016518498 A JP 2016518498A JP 2016526531 A5 JP2016526531 A5 JP 2016526531A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- administered
- viral particles
- particles per
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 239000002245 particle Substances 0.000 claims 25
- 230000003612 virological effect Effects 0.000 claims 18
- 241000701161 unidentified adenovirus Species 0.000 claims 13
- 241000700605 Viruses Species 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 230000000174 oncolytic effect Effects 0.000 claims 6
- 238000011287 therapeutic dose Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201310698A GB201310698D0 (en) | 2013-06-14 | 2013-06-14 | Method |
| GB1310698.4 | 2013-06-14 | ||
| GB201405140A GB201405140D0 (en) | 2014-03-22 | 2014-03-22 | Method |
| GB1405140.3 | 2014-03-22 | ||
| GB1406509.8 | 2014-04-10 | ||
| GB201406509A GB201406509D0 (en) | 2014-04-10 | 2014-04-10 | Method |
| PCT/EP2014/062284 WO2014198852A2 (en) | 2013-06-14 | 2014-06-12 | A dosing regime and formulations for type b adenoviruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020151615A Division JP2020203932A (ja) | 2013-06-14 | 2020-09-09 | Ｂ型アデノウイルスのための投与計画および製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526531A JP2016526531A (ja) | 2016-09-05 |
| JP2016526531A5 true JP2016526531A5 (enExample) | 2016-10-20 |
| JP6797680B2 JP6797680B2 (ja) | 2020-12-16 |
Family
ID=51162703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518498A Active JP6797680B2 (ja) | 2013-06-14 | 2014-06-12 | Ｂ型アデノウイルスのための投与計画および製剤 |
| JP2020151615A Pending JP2020203932A (ja) | 2013-06-14 | 2020-09-09 | Ｂ型アデノウイルスのための投与計画および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020151615A Pending JP2020203932A (ja) | 2013-06-14 | 2020-09-09 | Ｂ型アデノウイルスのための投与計画および製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11173186B2 (enExample) |
| EP (2) | EP3777870A1 (enExample) |
| JP (2) | JP6797680B2 (enExample) |
| KR (3) | KR20210054067A (enExample) |
| CN (2) | CN105431157A (enExample) |
| AU (2) | AU2014280123B2 (enExample) |
| BR (1) | BR112015030881A2 (enExample) |
| CA (2) | CA3176971A1 (enExample) |
| IL (1) | IL243071B (enExample) |
| RU (1) | RU2671558C2 (enExample) |
| SG (1) | SG11201510064WA (enExample) |
| WO (1) | WO2014198852A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201510197D0 (en) | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| CN110461323A (zh) * | 2017-03-31 | 2019-11-15 | 绪方久修 | 溶瘤病毒的增殖方法和抗肿瘤剂 |
| GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| WO2019189643A1 (ja) * | 2018-03-30 | 2019-10-03 | 国立大学法人東京大学 | 腫脹発生抑制型腫瘍溶解性ウイルス |
| CA3156171A1 (en) * | 2019-09-30 | 2021-04-08 | Candel Therapeutics, Inc. | CANCER TREATMENT BY COMBINED GENE-MEDIATED CYTOTOXIC IMMUNOTHERAPY AND ATR INHIBITOR |
| CN114469938A (zh) * | 2020-10-27 | 2022-05-13 | 中国医学科学院药物研究所 | 化合物bix02189在制备抗流感病毒药物中的应用 |
| CN114601838B (zh) * | 2022-04-29 | 2023-10-27 | 广东龙帆生物科技有限公司 | 一种azd8055在制备用于抗腺病毒感染的药物中的用途 |
| WO2024042231A1 (en) * | 2022-08-26 | 2024-02-29 | Universite De Namur | Adenovirus-based adjuvants for cancer treatment |
| AU2024277678A1 (en) | 2023-05-25 | 2025-11-27 | Dispatch Biotherapeutics, Inc. | Synthetic cancer antigens as targets for treating cancers |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170269A3 (en) | 1984-08-02 | 1987-09-23 | Kao Corporation | Medicated cosmetic compositions |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE19648650C2 (de) | 1996-01-29 | 1998-07-02 | Schering Ag | Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung |
| GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| NZ550147A (en) * | 1997-10-09 | 2008-09-26 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| ATE361988T1 (de) | 1998-12-09 | 2007-06-15 | Us Gov Health & Human Serv | Recombinanter vector, welcher mehrere kostimulatorische moleküle exprimiert und dessen verwenden |
| AU774437B2 (en) | 1999-02-22 | 2004-06-24 | Transgene S.A. | Method for obtaining a purified viral preparation |
| PL351553A1 (en) | 1999-04-09 | 2003-05-05 | Aventis Pharma Sa | Composition intended to preserve contagious adenoviruses of recombination type |
| US7279318B1 (en) | 1999-06-09 | 2007-10-09 | Hybrid Systems Limited | Modification of biological elements |
| ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| US20040167088A1 (en) * | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| AU2004260044B2 (en) * | 2003-07-18 | 2009-04-23 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
| SI1673398T1 (sl) | 2003-10-16 | 2011-05-31 | Micromet Ag | Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule |
| CA2555412C (en) | 2004-02-23 | 2013-06-25 | Crucell Holland B.V. | Virus purification methods |
| US7510868B2 (en) * | 2004-05-26 | 2009-03-31 | Paul Harden | Chimeric adenoviruses for use in cancer treatment |
| GB0416487D0 (en) | 2004-07-23 | 2004-08-25 | Isis Innovation | Modified virus |
| US7550296B2 (en) | 2004-12-01 | 2009-06-23 | Bayer Schering Pharma Ag | Generation of replication competent viruses for therapeutic use |
| US20060205080A1 (en) | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
| BRPI0615400A2 (pt) | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| CN1961961B (zh) | 2005-11-11 | 2010-05-26 | 深圳市源兴生物医药科技有限公司 | 一种药物制剂及其制备方法 |
| RU2382884C2 (ru) | 2006-07-10 | 2010-02-27 | Александр Владимирович Дидин | Сферическая объемная роторная машина и способ работы сферической объемной роторной машины |
| JP5448840B2 (ja) * | 2006-12-22 | 2014-03-19 | プシオクサス・セラピューティクス・リミテッド | 腫瘍退縮アデノウイルスの作出およびその使用 |
| US20110034560A1 (en) | 2008-01-29 | 2011-02-10 | Sven Jacobson | Liquid formulations of compounds active at sulfonylurea receptors |
| WO2009143610A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| CN101381742A (zh) | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| US20110243897A1 (en) | 2008-12-11 | 2011-10-06 | Leonard William Seymour | Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| BR112014003769B1 (pt) | 2011-08-23 | 2022-05-10 | Roche Glycart Ag | Molécula de ligação ao antígeno biespecífica ativadora de célula t, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t |
| WO2013074507A2 (en) | 2011-11-14 | 2013-05-23 | Regenerative Sciences, Llc | Suspended particle delivery systems and methods |
| PT2844282T (pt) | 2012-05-04 | 2019-07-23 | Pfizer | Antigénios associados à próstata e regimes de imunoterapêutica baseados em vacinas |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| WO2015040234A1 (en) | 2013-09-23 | 2015-03-26 | Crucell Holland B.V. | Adenovirus formulations |
| US9987314B2 (en) | 2013-10-25 | 2018-06-05 | Psioxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
| ES2717704T3 (es) | 2014-04-03 | 2019-06-24 | Igm Biosciences Inc | Cadena J modificada |
| KR20170044194A (ko) | 2014-08-27 | 2017-04-24 | 싸이오서스 테라퓨틱스 엘티디. | 아데노바이러스의 제조를 위한 공정 |
| SG10201901482XA (en) | 2015-04-30 | 2019-03-28 | Psioxus Therapeutics Ltd | Oncolytic adenovirus encoding a b7 protein |
-
2014
- 2014-06-12 EP EP20198714.6A patent/EP3777870A1/en active Pending
- 2014-06-12 RU RU2015152860A patent/RU2671558C2/ru active
- 2014-06-12 AU AU2014280123A patent/AU2014280123B2/en active Active
- 2014-06-12 CA CA3176971A patent/CA3176971A1/en active Pending
- 2014-06-12 EP EP14736650.4A patent/EP3007711B1/en not_active Revoked
- 2014-06-12 CN CN201480033427.XA patent/CN105431157A/zh active Pending
- 2014-06-12 CN CN202011432713.7A patent/CN112516179A/zh active Pending
- 2014-06-12 CA CA2914790A patent/CA2914790C/en active Active
- 2014-06-12 KR KR1020217013679A patent/KR20210054067A/ko not_active Ceased
- 2014-06-12 BR BR112015030881A patent/BR112015030881A2/pt not_active Application Discontinuation
- 2014-06-12 KR KR1020217041147A patent/KR20210156857A/ko not_active Ceased
- 2014-06-12 WO PCT/EP2014/062284 patent/WO2014198852A2/en not_active Ceased
- 2014-06-12 SG SG11201510064WA patent/SG11201510064WA/en unknown
- 2014-06-12 US US14/896,294 patent/US11173186B2/en active Active
- 2014-06-12 JP JP2016518498A patent/JP6797680B2/ja active Active
- 2014-06-12 KR KR1020167000214A patent/KR20160026970A/ko not_active Ceased
-
2015
- 2015-12-09 IL IL24307115A patent/IL243071B/en active IP Right Revival
-
2020
- 2020-02-14 AU AU2020201101A patent/AU2020201101B2/en active Active
- 2020-09-09 JP JP2020151615A patent/JP2020203932A/ja active Pending
-
2021
- 2021-09-23 US US17/448,549 patent/US12350302B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526531A5 (enExample) | ||
| RU2015152860A (ru) | Режим введения и составы для аденовирусов типа в | |
| Yasinjan et al. | Immunotherapy: a promising approach for glioma treatment | |
| Zhu et al. | Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways | |
| Kanagavelu et al. | In vivo effects of lattice radiation therapy on local and distant lung cancer: potential role of immunomodulation | |
| Huang et al. | Time-programmed delivery of sorafenib and anti-CD47 antibody via a double-layer-gel matrix for postsurgical treatment of breast cancer | |
| Seicean et al. | New targeted therapies in pancreatic cancer | |
| JP2012067116A5 (enExample) | ||
| JP2019065028A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| JP2013189456A5 (enExample) | ||
| JP2020509024A5 (enExample) | ||
| JP2015187125A5 (enExample) | ||
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| Frieboes et al. | Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy | |
| JP2016515586A5 (enExample) | ||
| JP2016501528A5 (enExample) | ||
| Karapetyan et al. | Radiation dose, schedule, and novel systemic targets for radio-immunotherapy combinations | |
| JP2017503846A5 (enExample) | ||
| Wang et al. | The pros and cons of dying tumour cells in adaptive immune responses | |
| Holtermann et al. | Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors: A. Holtermann et al. | |
| Jiang et al. | Low‐dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer | |
| Warricker et al. | The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma | |
| He et al. | Role of tumor-associated macrophages in breast cancer immunotherapy |